不同剂量阿托伐他汀对急性冠状动脉综合征患者血清明胶酶B水平影响的观察

目的探讨急性冠状动脉综合征(ACS)患者住院早期,应用不同剂量阿托伐他汀后,血清明胶酶B(MMP-9)及基质金属蛋白酶组织抑制因子-1(TIMP-1)水平的变化。方法选择ACS患者82例,随机分为三组:阿托伐他汀10mg组30例,阿托伐他汀20mg组30例,阿托伐他汀40mg组22例,均于入院24h内开始给予阿托伐他汀治疗,测定三组入院时及治疗2周后血清MMP-9及TIMP1水平的变化。结果ACS患者早期应用阿托伐他汀可明显降低血清MMP-9水平,提高TIMP-1水平,阿托伐他汀20mg组及阿托伐他汀40mg组均优于阿托伐他汀10mg组,相比有显著性差异,阿托伐他汀40mg组优于阿托伐他汀20mg组,但相比无显著性差异。结论ACS患者早期应用阿托伐他汀可降低血清MMP-9水平,升高TIMP-1水平,阿托伐他汀20mg作用明显优于10mg,阿托伐他汀40mg与20mg相比,疗效无显著性差异。

Effect of atorvastatin with different dosage on serum level of matrix metalloprotease-9 in patients with acute coronary syndromes

Object To investigate the effect of early intervention by atorvastatin with different dosage on serum level of MMP-9 and TIMP-1 in patients with ACS.Methods 82 patients with ACS were divided randomly into three group:atorvastatin group 10mg(n=30),atorvastatin group 20mg(n=30),atorvastatin group 40mg(n=22).All patients take(atorvastatin) inside of 24h after admission.Blood samples were examined at admission and two weeks after the therapy of atorvastatin in three group patients.Results The use of atorvastatin in early admission period of ACS was significantly reduced serum level of MMP-9 and increased serum level on TIMP-1,which were more obviously in the group of 20mg/d and the group of 40mg/d than in group of 10mg/d.There was not significant difference between in group of 20mg/d and in group of 40mg/d.Conclusion The use of atorvastatin 20mg/d seems better than that of 10mg/d in decrease of MMP-9 and increase of TIMP-1.